Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Davis, James A  [Clear All Filters]
2012
Majka SM, Miller HL, Sullivan T, Erickson PF, Kong R, Weiser-Evans M, Nemenoff R, Moldovan R, Morandi SA, Davis JA, et al. Adipose lineage specification of bone marrow-derived myeloid cells. Adipocyte. 2012;1(4):215-229.
2022
Davis JA, Shockley A, Glode AE. Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma. J Oncol Pharm Pract. 2022:10781552211073575.
2023
Davis JA, Sborov DW, Wesson W, Julian K, Abdallah A-O, McGuirk JP, Ahmed N, Hashmi H. Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy. Transplant Cell Ther. 2023.
Thurlapati A, Wesson W, Davis JA, Gaffney KJ, Weeda E, Velayati A, Bakos JK, Granger K, Smith D, Maldonado AP, et al. Impact of Cytogenetic Abnormalities, Induction and Maintenance Regimens on Outcomes After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma: A Decade-Long Real-World Experience. J Hematol. 2023;12(6):243-254.
Davis JA, Thurlapati A, Weeda E, Gaffney KJ, Smith D, Maldonado A, Granger K, Martin KE, Williams YM, Herrington T, et al. Impact of race and ethnicity on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma. Ann Hematol. 2023.
Thurlapati A, McGann M, Davis JA, Granger K, Roubal K, Smith D, Gaffney KJ, Cendagorta A, Herbst A, Hendrickson L, et al. Role of tixagevimab-cilgavimab in preventing SARS-CoV-2 in hematopoietic stem cell transplant and chimeric antigen receptor T-cell therapy recipients. J Med Virol. 2023;95(8):e29027.
Hashmi H, Davis JA, Abdallah A-O. 'A Stitch in Time Saves Nine': Early stem cell transplant continues to improve outcomes in patients with newly diagnosed multiple myeloma. Expert Rev Hematol. 2023.
2024
Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, Oliver-Caldes A, Stölzel F, Rathje K, Fischer L, et al. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2024:JCO2302232.
Davis JA, McGann M, Marini J, Hashmi H. How to manage prolonged immune effector cell-associated hematotoxicity (ICAHT) related to BCMA-directed myeloma therapy. Expert Rev Anticancer Ther. 2024.
Gaffney KJ, Bakos JK, Velayati A, Davis JA, Thurlapati A, Weeda E, Maldonado A, Granger K, Butcher C, Herrington T, et al. Impact of age, obesity, and renal impairment on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma. J Oncol Pharm Pract. 2024:10781552231224361.